Published in AIDS Res Hum Retroviruses on January 01, 2007
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med (2009) 8.45
The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc Natl Acad Sci U S A (2013) 1.80
HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol (2010) 1.57
Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters. Retrovirology (2013) 1.00
The evolution of HIV: inferences using phylogenetics. Mol Phylogenet Evol (2011) 0.94
T cell subsets in HIV infected patients after successful combination antiretroviral therapy: impact on survival after 12 years. PLoS One (2012) 0.91
The Latent Reservoir for HIV-1: How Immunologic Memory and Clonal Expansion Contribute to HIV-1 Persistence. J Immunol (2016) 0.82
A phylogenetic and Markov model approach for the reconstruction of mutational pathways of drug resistance. Bioinformatics (2009) 0.82
Molecular evolution of HIV-1 CRF01_AE Env in Thai patients. PLoS One (2011) 0.81
Human Immunodeficiency Virus Playing Hide-and-Seek: Understanding the TFH Cell Reservoir and Proposing Strategies to Overcome the Follicle Sanctuary. Front Immunol (2017) 0.75
A human phenome-interactome network of protein complexes implicated in genetic disorders. Nat Biotechnol (2007) 9.90
Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med (2007) 6.30
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis (2010) 3.37
Syphilis and human immunodeficiency virus (HIV)-1 coinfection: influence on CD4 T-cell count, HIV-1 viral load, and treatment response. Sex Transm Dis (2006) 2.90
Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis (2009) 2.73
Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis (2007) 2.69
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS (2010) 2.51
Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis (2012) 2.39
Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis (2004) 2.02
Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol (2009) 1.83
The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics (2009) 1.80
Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med (2002) 1.70
Mortality in siblings of patients coinfected with HIV and hepatitis C virus. J Infect Dis (2006) 1.68
Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. AIDS (2011) 1.57
HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol (2010) 1.57
Schistosomiasis and HIV-1 infection in rural Zimbabwe: effect of treatment of schistosomiasis on CD4 cell count and plasma HIV-1 RNA load. J Infect Dis (2005) 1.56
Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome. Clin Infect Dis (2010) 1.52
Expression of fibroblast growth factor-21 in muscle is associated with lipodystrophy, insulin resistance and lipid disturbances in patients with HIV. PLoS One (2013) 1.50
Right and left ventricular cardiac function in a developed world population with human immunodeficiency virus studied with radionuclide ventriculography. Am Heart J (2004) 1.46
Improved survival in HIV-infected persons: consequences and perspectives. J Antimicrob Chemother (2007) 1.45
Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS (2012) 1.45
K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir Ther (2003) 1.42
Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One (2011) 1.42
Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol (2012) 1.39
Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clin Infect Dis (2011) 1.37
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis (2006) 1.35
Finding coevolving amino acid residues using row and column weighting of mutual information and multi-dimensional amino acid representation. Algorithms Mol Biol (2007) 1.25
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis (2003) 1.25
Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis (2014) 1.25
Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS (2010) 1.23
Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy. J Infect Dis (2004) 1.22
High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr (2005) 1.21
Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study. Clin Infect Dis (2005) 1.19
A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Antivir Ther (2005) 1.18
Late presenters, repeated testing, and missed opportunities in a Danish nationwide HIV cohort. Scand J Infect Dis (2011) 1.17
Predictors of mortality in a cohort of HIV-1-infected adults in rural Africa. J Acquir Immune Defic Syndr (2007) 1.17
Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study. Clin Infect Dis (2008) 1.14
MaxAlign: maximizing usable data in an alignment. BMC Bioinformatics (2007) 1.13
The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish cohort study 1999-2005. Antivir Ther (2009) 1.12
Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes. AIDS (2009) 1.12
Reduced mortality and CD4 cell loss among carriers of the interleukin-10 -1082G allele in a Zimbabwean cohort of HIV-1-infected adults. AIDS (2007) 1.11
Retention in a public healthcare system with free access to treatment: a Danish nationwide HIV cohort study. AIDS (2012) 1.10
Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study. PLoS One (2012) 1.08
The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. AIDS (2007) 1.07
Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals. AIDS (2005) 1.06
Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations. J Virol (2009) 1.05
Risk of cancer among HIV-infected individuals compared to the background population: impact of smoking and HIV. AIDS (2014) 1.05
Patients' answers to simple questions about treatment satisfaction and adherence and depression are associated with failure of HAART: a cross-sectional survey. AIDS Patient Care STDS (2005) 1.02
Schistosomiasis and HIV in rural Zimbabwe: efficacy of treatment of schistosomiasis in individuals with HIV coinfection. Clin Infect Dis (2006) 1.02
Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr (2004) 1.02
Addressing the fear and consequences of stigmatization - a necessary step towards making HAART accessible to women in Tanzania: a qualitative study. AIDS Res Ther (2011) 1.02
Declining prevalence of HIV-infected individuals at risk of transmitting drug-resistant HIV in Denmark during 1997-2004. Antivir Ther (2006) 1.02
InterMap3D: predicting and visualizing co-evolving protein residues. Bioinformatics (2009) 1.01
Limited cross-border infections in patients newly diagnosed with HIV in Europe. Retrovirology (2013) 1.01
Statin therapy and mortality in HIV-infected individuals; a Danish nationwide population-based cohort study. PLoS One (2013) 1.01
Autonomic dysfunction in HIV patients on antiretroviral therapy: studies of heart rate variability. Clin Physiol Funct Imaging (2007) 1.01
Persistent inflammation and endothelial activation in HIV-1 infected patients after 12 years of antiretroviral therapy. PLoS One (2013) 1.00
Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS (2003) 0.99
Early infant diagnosis of HIV in three regions in Tanzania; successes and challenges. BMC Public Health (2013) 0.99
Microbial translocation in HIV infection is associated with dyslipidemia, insulin resistance, and risk of myocardial infarction. J Acquir Immune Defic Syndr (2013) 0.99
Molecular phylogenetics of transmitted drug resistance in newly diagnosed HIV Type 1 individuals in Denmark: a nation-wide study. AIDS Res Hum Retroviruses (2011) 0.99
Changes in lung function of HIV-infected patients: a 4.5-year follow-up study. Clin Physiol Funct Imaging (2012) 0.98
Impact of injecting drug use on mortality in Danish HIV-infected patients: a nation-wide population-based cohort study. Addiction (2010) 0.98
Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: a cohort study. BMC Infect Dis (2010) 0.98
Lung cancer in HIV patients and their parents: a Danish cohort study. BMC Cancer (2011) 0.98
Stable incidence of HIV diagnoses among Danish MSM despite increased engagement in unsafe sex. J Acquir Immune Defic Syndr (2012) 0.97
T-cell subset distribution in HIV-1-infected patients after 12 years of treatment-induced viremic suppression. J Acquir Immune Defic Syndr (2012) 0.97
Low level of regulatory T cells and maintenance of balance between regulatory T cells and TH17 cells in HIV-1-infected elite controllers. J Acquir Immune Defic Syndr (2011) 0.97
Persisting inflammation and chronic immune activation but intact cognitive function in HIV-infected patients after long-term treatment with combination antiretroviral therapy. J Acquir Immune Defic Syndr (2013) 0.96
Physicians' communication with patients about adherence to HIV medication in San Francisco and Copenhagen: a qualitative study using Grounded Theory. BMC Health Serv Res (2006) 0.96
Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. BMC Infect Dis (2014) 0.96
Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS (2003) 0.95
Introduction of HIV type 1 into an isolated population: molecular epidemiologic study from Greenland. AIDS Res Hum Retroviruses (2007) 0.95
Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study. Scand J Infect Dis (2010) 0.95
APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon. PLoS Genet (2012) 0.95
Reduction in coronary and peripheral vasomotor function in patients with HIV after initiation of antiretroviral therapy: a longitudinal study with positron emission tomography and flow-mediated dilation. Nucl Med Commun (2010) 0.95
Plasma cytokine levels in Tanzanian HIV-1-infected adults and the effect of antiretroviral treatment. J Acquir Immune Defic Syndr (2009) 0.94
Inpatient admissions and outpatient visits in persons with and without HIV infection in Denmark, 1995-2007. AIDS (2010) 0.94
Unmeasured confounding caused slightly better response to HAART within than outside a randomized controlled trial. J Clin Epidemiol (2007) 0.94
Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study. Scand J Infect Dis (2012) 0.93
Earlier testing for HIV--how do we prevent late presentation? Antivir Ther (2010) 0.93
Lymphogranuloma venereum proctitis: a differential diagnose to inflammatory bowel disease. Scand J Gastroenterol (2010) 0.92
Morbidity and risk of subsequent diagnosis of HIV: a population based case control study identifying indicator diseases for HIV infection. PLoS One (2012) 0.91
T cell subsets in HIV infected patients after successful combination antiretroviral therapy: impact on survival after 12 years. PLoS One (2012) 0.91
Long-Term Mortality in HIV-Infected Individuals 50 Years or Older: A Nationwide, Population-Based Cohort Study. J Acquir Immune Defic Syndr (2016) 0.91
Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K). AIDS (2007) 0.91
Comorbidity acquired before HIV diagnosis and mortality in persons infected and uninfected with HIV: a Danish population-based cohort study. J Acquir Immune Defic Syndr (2011) 0.90
A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial. Antivir Ther (2006) 0.90
Soluble CD163 does not predict first-time myocardial infarction in patients infected with human immunodeficiency virus: a nested case-control study. BMC Infect Dis (2013) 0.89